Exclusive | GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree - WSJ
Source: WSJ ·
Exclusive | GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree WSJGSK sees its return to cancer start to pay off STATGSK is expecting its cancer drug clinical pipeline to nearly double in 2027 QuartzESMO: GSK cancer R&D chief says mo-rez data ‘reinforces our belief’ in ADC as phase 3 push ramps up Fierce BiotechWhat Could GSK (LSE:GSK) Oncology Progress Mean For…